Sanara MedTech (SMTI) Stock Price, News & Analysis

Company Overview

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Key Stats

• Today's Range: $37.29 to $38.53
• 50-Day Range: $29.00 to $37.70
• 52-Week Range: $26.00 to $43.25
• Volume: 45,868 shs
• Average Volume: 30,015 shs
• Market Capitalization: $329.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.00
• Consensus Rating: Buy

Sanara MedTech Stock Analysis - MarketRank™

Sanara MedTech scored higher than 20% of companies evaluated by MarketBeat, and ranked 869th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Sanara MedTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Sanara MedTech has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sanara MedTech is -38.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sanara MedTech is -38.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sanara MedTech has a P/B Ratio of 8.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.68% of the float of Sanara MedTech has been sold short.

Short Interest Ratio / Days to Cover

Sanara MedTech has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in Sanara MedTech has recently increased by 8.85%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sanara MedTech does not currently pay a dividend.

Dividend Growth

Sanara MedTech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.68% of the float of Sanara MedTech has been sold short.

Short Interest Ratio / Days to Cover

Sanara MedTech has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in Sanara MedTech has recently increased by 8.85%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: N/A

News Sentiment

Sanara MedTech has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

Search Interest

Only 1 people have searched for SMTI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sanara MedTech insiders have not sold or bought any company stock.

Percentage Held by Insiders

54.10% of the stock of Sanara MedTech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 8.10% of the stock of Sanara MedTech is held by institutions.

SMTI Stock Analysis - Frequently Asked Questions

How have SMTI shares performed this year?

Sanara MedTech's stock was trading at $41.10 at the start of the year. Since then, SMTI stock has decreased by 8.3% and is now trading at $37.70.
View the best growth stocks for 2024 here.

How were Sanara MedTech's earnings last quarter?

Sanara MedTech Inc. (NASDAQ:SMTI) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.62) by $0.28. The firm had revenue of $21.67 million for the quarter. Sanara MedTech had a negative net margin of 10.71% and a negative trailing twelve-month return on equity of 19.86%.

Who are Sanara MedTech's major shareholders?

Sanara MedTech's top institutional investors include Geode Capital Management LLC (1.01%), State Street Corp (0.67%), Janney Montgomery Scott LLC (0.38%) and Barclays PLC (0.07%). Insiders that own company stock include Zachary B Fleming and Shawn M Bowman.
View institutional ownership trends.

How do I buy shares of Sanara MedTech?

Shares of SMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Sanara MedTech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sanara MedTech investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 11/24/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/24/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical appliances & supplies
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:SMTI
• CUSIP: N/A
• CIK: 714256
• Web: www.wndm.com
• Phone: (817) 529-2300
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $44.00
• High Stock Price Target: $44.00
• Low Stock Price Target: $44.00
• Potential Upside/Downside: +16.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,300,000.00
• Net Margins: -10.71%
• Pretax Margin: -10.86%
• Return on Equity: -19.86%
• Return on Assets: -10.91%

Debt

• Debt-to-Equity Ratio: 0.76
• Current Ratio: 2.23
• Quick Ratio: 2.02

Sales & Book Value

• Annual Sales: $64.99 million
• Price / Sales: 5.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.51 per share
• Price / Book: 8.36

Miscellaneous

• Outstanding Shares: 8,740,000
• Free Float: 4,012,000
• Market Cap: $329.50 million
• Optionable: Not Optionable
• Beta: 1.55